LDLR and atherosclerosis: To address this fully, future studies utilizing tools (e.g. siRNA) that selectively silence Nox2β or Nox2 in vivo, and multiple models of atherosclerosis (i.e. ApoE−/− and LDLR−/− mice), are required.